News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Expanding diagnostics footprint in East India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
_256_384.png)
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Company hires life science veteran Jessica Cao to join management team
Subscribe To Our Newsletter & Stay Updated
